VivoSim Labs Inc(VIVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.47 | Insider Own | 16.62% | Shs Outstand | 16.6M | Perf Week | -2.54% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.36% | Shs Float | 13.8M | Perf Month | -14.29% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 11.17% | Short Float | 4.7% | Perf Quarter | -57.24% |
| Income | -0.01B | P/S | 20.76 | EPS this Y | - | Inst Trans | 0.46% | Short Ratio | 0.63 | Perf Half Y | -89.55% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -155.93% | Short Interest | 0.65M | Perf YTD | -92.38% |
| Book/sh | -0.73 | P/C | 1.37 | EPS past 3/5Y | 39.18% 28.81% | ROE | -343.1% | 52W High | -95.94% ($3.40) | Perf Year | -93.9% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | -29.26% - | ROIC | - | 52W Low | 11.21% ($0.12) | Perf 3Y | -99.15% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -194.95% | Gross Margin | -73.21% | Volatility(W/M) | 19.09% 13.3% | Perf 5Y | -99.8% |
| Dividend TTM | - | EV/Sales | 8.49 | Sales Y/Y TTM | -21.13% | Oper. Margin | -10116.96% | ATR (14) | 0.02 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 1.7 | EPS Q/Q | 77.51% | Profit Margin | -11016.07% | RSI (14) | 39.08 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.7 | Sales Q/Q | -51.35% | SMA20 | -8.93% ($0.15) | Beta | 1.55 | Target Price | $64.8 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -30.11% ($0.2) | Rel Volume | 1.57 | Prev Close | $0.15 |
| Employees | 15 | LT Debt/Eq | - | EPS/Sales Surpr. | 46.15% -26.83% | SMA200 | -86.12% ($1.01) | Avg Volume(3M) | 1.03M | Price | $0.14 |
| IPO | 2012/2/14 | Option/Short | No/Yes | Trades | 918 | Volume | 1,614,967 | Change | -10.8% |
🧬 This is a non-clinical research services company that uses human liver and intestinal tissue models made with 3D bioprinting to pre-evaluate the toxicity and efficacy of new drug candidates. Its former name was Organovo, and it changed its name to Vivovision Labs in 2025. It is a micro-cap stock with a very small revenue base.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded more than usual. That is 157% of its average volume.
VIVS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,076. Peers typically go for $885.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.2%.
Tap to view numbers
It ranks #570 of 597 in the industry
Based on market cap of $2M.
FAQ
What kind of company is VIVS?
VIVS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VIVS?
The market cap of VIVS is approximately $2M, ranking 5,763 within its sector.
What is the 52-week high and low for VIVS?
VIVS has recorded a 52-week high of $3.40 and a low of $0.12.
